Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
14.8%
0.81
1.32
0.70
8.00%
-47.4%
51.48
Nifty 500 benchmark
15.2%
0.39
0.58
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
36 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
4,778
-36.7%
14.0%
175.8%
24%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
102%
65%
0.72
11.3%
0.55
17.39
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 36 months this scheme and
Nifty 500 share.
Nippon India Pharma Fund
Regular Plan · Bonus Option
Allocation
By asset
Equity
97.31%
Cash & Equivalents
2.69%
By market cap
Large Cap
29.71%
Mid Cap
39.02%
Small Cap
28.04%
Unclassified
0.54%
Concentration
Number of stocks
36
Top 5 stocks
36.44%
Top 10 stocks
56.35%
Top 20 stocks
80.39%
Lines in the filing
39
Largest holding
11.71%
Largest sector
Pharmaceuticals & Biotechnology 73.97%
Effective stocks
22.1
Sectors held
4
Cash
2.69%
Effective stocks is what the concentration works out to: a fund holding
36 names but most of its money in a few
behaves like a fund of 22. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
73.97%
Healthcare Services
20.27%
Cash & Equivalents
2.69%
Retailing
2.53%
Healthcare Equipment & Supplies
0.54%
Nippon India Pharma Fund
Regular Plan · Bonus Option · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Sun Pharmaceutical Industries Limited
Pharmaceuticals & Biotechnology
5,906,349
1,073
11.71%
2
Divi's Laboratories Limited
Pharmaceuticals & Biotechnology
700,754
651
7.10%
3
Lupin Limited
Pharmaceuticals & Biotechnology
2,783,991
565
6.17%
4
Cipla Limited
Pharmaceuticals & Biotechnology
4,095,054
551
6.01%
5
Dr. Reddy's Laboratories Limited
Pharmaceuticals & Biotechnology
4,049,746
499
5.45%
6
Apollo Hospitals Enterprise Limited
Healthcare Services
548,795
448
4.89%
7
Mankind Pharma Limited
Pharmaceuticals & Biotechnology
1,603,562
402
4.38%
8
Sai Life Sciences Limited
Pharmaceuticals & Biotechnology
2,355,745
359
3.92%
9
Ajanta Pharma Limited
Pharmaceuticals & Biotechnology
913,918
331
3.61%
10
GlaxoSmithKline Pharmaceuticals Limited
Pharmaceuticals & Biotechnology
1,029,460
285
3.11%
11
IPCA Laboratories Limited
Pharmaceuticals & Biotechnology
1,364,742
263
2.87%
12
Triparty Repo
Unclassified
—
258
2.81%
13
Max Healthcare Institute Limited
Healthcare Services
2,658,082
247
2.70%
14
Vijaya Diagnostic Centre Limited
Healthcare Services
1,671,618
240
2.62%
15
MedPlus Health Services Limited
Retailing
3,545,229
232
2.53%
16
Gland Pharma Limited
Pharmaceuticals & Biotechnology
800,549
232
2.53%
17
Abbott India Limited
Pharmaceuticals & Biotechnology
78,546
213
2.32%
18
Thyrocare Technologies Limited
Healthcare Services
3,837,967
205
2.24%
19
Piramal Pharma Limited
Pharmaceuticals & Biotechnology
9,937,272
205
2.24%
20
Dr. Lal Path Labs Limited
Healthcare Services
1,000,578
199
2.17%
21
Alkem Laboratories Limited
Pharmaceuticals & Biotechnology
323,678
167
1.82%
22
Aurobindo Pharma Limited
Pharmaceuticals & Biotechnology
902,630
151
1.65%
23
Narayana Hrudayalaya Limited
Healthcare Services
823,911
148
1.61%
24
Suraksha Diagnostic Limited
Healthcare Services
3,896,349
138
1.51%
25
Syngene International Limited
Healthcare Services
3,501,497
128
1.40%
26
Emcure Pharmaceuticals Limited
Pharmaceuticals & Biotechnology
640,910
125
1.36%
27
Pfizer Limited
Pharmaceuticals & Biotechnology
318,249
123
1.35%
28
Akums Drugs and Pharmaceuticals Limited
Pharmaceuticals & Biotechnology
1,351,672
111
1.21%
29
Anthem Biosciences Limited
Pharmaceuticals & Biotechnology
1,275,040
109
1.19%
30
Fortis Healthcare Limited
Healthcare Services
1,346,128
104
1.13%
Nippon India Pharma Fund
Regular Plan · Bonus Option · where the money sits
What the manager did last month
Between the filings of 30 Jun 2026 and 31 Jul 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹138 cr
₹124 cr
0
0
+3.07%
Stock
Shares traded
Shares
Price
Value ₹ cr
Added to
Piramal Pharma Limited
4,437,272
+80.7%
+16.4%
86.8
Sanofi India Limited
70,000
+30.4%
-2.6%
23.2
Biocon Limited
534,697
+36.4%
+1.8%
22.8
GlaxoSmithKline Pharmaceuticals Limited
15,615
+1.7%
+8.4%
4.2
Abbott India Limited
463
+0.6%
+9.3%
1.3
Trimmed
Dr. Reddy's Laboratories Limited
400,000
-9.0%
-15.4%
45.9
Vijaya Diagnostic Centre Limited
200,000
-10.7%
-0.6%
26.9
Thyrocare Technologies Limited
350,282
-8.0%
+5.4%
20.3
Aurobindo Pharma Limited
100,000
-10.0%
+0.1%
15.8
Mankind Pharma Limited
26,766
-1.9%
-3.0%
6.6
Akums Drugs and Pharmaceuticals Limited
84,034
-5.6%
+5.7%
5.5
Dr. Lal Path Labs Limited
17,646
-1.7%
+15.7%
3.4
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹926,630
₹326,630
17.43%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 30 Oct 2026.
